Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 36
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 1751 | ELECTDIS | 8 | 225% | 3 | 3 | 2022–2024 |
| 1752 | ELIXIR MEDICAL | 8 | 00% | 4 | 4 | 2022–2025 |
| 1753 | ELYSIS PARTNERSHIP | 8 | 00% | 0 | 8 | 2022–2024 |
| 1754 | ENANTA PHARMACEUTICALS | 8 | 112.5% | 1 | 6 | 2022–2026 |
| 1755 | ENTEK ASIA | 8 | 225% | 0 | 6 | 2022–2025 |
| 1756 | ENTEROBIOME | 8 | 112.5% | 0 | 7 | 2022–2024 |
| 1757 | ENTRADA THERAPEUTICS | 8 | 00% | 0 | 8 | 2023–2026 |
| 1758 | ESCO GROUP | 8 | 00% | 1 | 7 | 2022–2024 |
| 1759 | FAIRLIFE | 8 | 00% | 1 | 7 | 2022–2025 |
| 1760 | FEDERAL MOGUL POWERTRAIN | 8 | 112.5% | 0 | 7 | 2022–2024 |
| 1761 | FIBERTEX PERSONAL CARE A S | 8 | 225% | 1 | 5 | 2016–2026 |
| 1762 | FOSS ANALYTICAL A S | 8 | 112.5% | 3 | 4 | 2022–2026 |
| 1763 | FREEDMAN ELECTRONICS PTY | 8 | 00% | 0 | 8 | 2023–2025 |
| 1764 | FUJITSU FRONTECH | 8 | 112.5% | 3 | 4 | 2022–2024 |
| 1765 | GARUDA THERAPEUTICS | 8 | 00% | 0 | 8 | 2023–2025 |
| 1766 | GB BOUCHERIE | 8 | 00% | 1 | 7 | 2022–2025 |
| 1767 | GE INFRASTRUCTURE TECHNOLOGY | 8 | 00% | 0 | 8 | 2024–2025 |
| 1768 | GENFIT | 8 | 00% | 0 | 8 | 2022–2026 |
| 1769 | GETINGE LIFE SCIENCE FRANCE | 8 | 225% | 0 | 6 | 2021–2026 |
| 1770 | GLANCE INMOBI | 8 | 00% | 0 | 8 | 2023–2024 |
| 1771 | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC | 8 | 00% | 0 | 8 | 2024–2026 |
| 1772 | GLUETACS THERAPEUTICS SHANGHAI | 8 | 00% | 0 | 8 | 2024–2026 |
| 1773 | GMP BIOTECHNOLOGY | 8 | 00% | 0 | 8 | 2023–2026 |
| 1774 | GRIREM ADVANCED MATERIALS | 8 | 225% | 0 | 6 | 2022–2024 |
| 1775 | GRIREM HI TECH | 8 | 225% | 0 | 6 | 2022–2024 |
| 1776 | GUANGDONG CARRIER HEATING VENTILATION AND AIR CONDITIONING | 8 | 112.5% | 0 | 7 | 2023–2024 |
| 1777 | GUANGDONG OPK SMART HOME TECHNOLOGY | 8 | 00% | 0 | 8 | 2022–2026 |
| 1778 | HEMA MASCHINEN UND APPARATESCHUTZ | 8 | 00% | 0 | 8 | 2023–2026 |
| 1779 | HENDRICKSON USA L L C | 8 | 112.5% | 0 | 7 | 2023–2025 |
| 1780 | HERAEUS QUARZGLAS KG | 8 | 225% | 0 | 6 | 2022–2024 |
| 1781 | HL MANDO | 8 | 00% | 0 | 8 | 2023–2025 |
| 1782 | HUNTSMAN ADVANCED MATERIALS AMERICAS | 8 | 450% | 0 | 4 | 2022–2026 |
| 1783 | HYSATA PTY | 8 | 00% | 0 | 8 | 2023–2025 |
| 1784 | ICOSAVAX | 8 | 00% | 0 | 8 | 2023–2025 |
| 1785 | IDEAYA BIOSCIENCES | 8 | 00% | 2 | 6 | 2022–2026 |
| 1786 | IDEMIA FRANCE | 8 | 112.5% | 0 | 7 | 2021–2025 |
| 1787 | IMCYSE | 8 | 112.5% | 2 | 5 | 2019–2024 |
| 1788 | IMMUNOGEN | 8 | 00% | 2 | 6 | 2023–2025 |
| 1789 | IMPOSSIBLE FOODS | 8 | 00% | 0 | 8 | 2022–2026 |
| 1790 | INCREDO | 8 | 00% | 1 | 7 | 2023–2025 |
| 1791 | INDUSTRIE DE NORA | 8 | 00% | 0 | 8 | 2022–2026 |
| 1792 | INK INVENT IP | 8 | 112.5% | 0 | 7 | 2022–2025 |
| 1793 | INNATE PHARMA | 8 | 00% | 0 | 8 | 2023–2025 |
| 1794 | INTER IKEA SYSTEMS | 8 | 112.5% | 0 | 7 | 2022–2025 |
| 1795 | INVOX BELGIUM | 8 | 112.5% | 0 | 7 | 2021–2026 |
| 1796 | J D THEILE KG | 8 | 00% | 0 | 8 | 2022–2024 |
| 1797 | JAGUAR LAND ROVER | 8 | 00% | 0 | 8 | 2025–2025 |
| 1798 | JAZZ PHARMACEUTICALS IRELAND | 8 | 00% | 0 | 8 | 2023–2025 |
| 1799 | JIANGSU GOLDWIND SCIENCE TECHNOLOGY | 8 | 112.5% | 1 | 6 | 2022–2024 |
| 1800 | JIANGSU HENGRUI MEDICINE | 8 | 00% | 1 | 7 | 2022–2022 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →